Why the study?
Although digoxin was considered an effective treatment for HF, the supporting evidence is conflicting.
Does digoxin improve efficacy and safety in patients experiencing heart failure with a reduced ejection fraction (HFrEF)?
Does digoxin improve efficacy and safety in patients experiencing heart failure with a reduced ejection fraction (HFrEF)?
The review highlights that evidence supporting digoxin use in HFrEF is conflicting and calls for further randomized trials.
Current conflicting evidence precludes routine digoxin recommendation in HFrEF; leaves open its role pending new randomized trials.
In this review, we evaluated the literature on the benefits and deleterious effects of digoxin in heart failure (HF) with reduced ejection fraction (EF). Although digoxin was considered an effective treatment for HF, the supporting evidence is conflicting. Before the conventional use of modern HF therapies, digoxin was widely used for symptomatic relief on these patients. Further randomized trials are required to reach a definite conclusion about its efficacy and safety in patients experiencing HF with a reduced EF (HFrEF).
No takes yet. Share an insight, caveat, or question.
Parikh et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: